Australia markets open in 37 minutes

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.7300-0.0200 (-1.14%)
At close: 04:00PM EDT
1.7700 +0.04 (+2.31%)
After hours: 05:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7500
Open1.7500
Bid1.7200 x 1000
Ask1.8100 x 1300
Day's range1.7100 - 1.7600
52-week range1.7100 - 6.8400
Volume73,792
Avg. volume730,674
Market cap103.774M
Beta (5Y monthly)1.82
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

    BOSTON, June 13, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY.

  • Business Wire

    Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

    BOSTON, June 10, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces the appointment of Ivan M. Borrello, M.D. to its Board of Directors, effective June 9, 2022. Dr. Borrello is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a renowned physician and author who has made major contributions to better

  • Business Wire

    Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

    BOSTON, June 02, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced completion of the rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.